Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.

Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS.

Am J Clin Oncol. 2008 Apr;31(2):173-81. doi: 10.1097/COC.0b013e3181573e6b.

PMID:
18391603
2.

Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.

Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ.

J Immunother. 2008 Jan;31(1):72-80.

PMID:
18157014
3.

Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.

Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF.

Clin Cancer Res. 2001 Jul;7(7):1882-7.

4.

Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.

Spanknebel K, Cheung KY, Stoutenburg J, Hurst-Wicker K, Hesdorffer C, Rn GD, Kaufman AH.

Ann Surg Oncol. 2005 May;12(5):381-90. Epub 2005 Apr 4.

PMID:
15915372
5.

Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?

Hurst R, White DE, Heiss J, Lee DS, Rosenberg SA, Schwartzentruber DJ.

J Immunother. 1999 Jul;22(4):356-62.

PMID:
10404437
6.

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.

Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E.

Cancer Immunol Immunother. 2011 Feb;60(2):261-71. doi: 10.1007/s00262-010-0935-9. Epub 2010 Nov 11.

PMID:
21069322
7.

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.

Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F, Velu T.

Cancer Immunol Immunother. 2006 Jul;55(7):819-29. Epub 2005 Sep 27.

PMID:
16187085
8.

Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.

Marroquin CE, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ.

J Immunother. 2000 May-Jun;23(3):387-92.

PMID:
10838668
9.

Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma.

Schrader AJ, Heidenreich A, Hegele A, Olbert P, Ohlmann CH, Varga Z, von Knobloch R, Hofmann R.

Anticancer Drugs. 2005 Jun;16(5):581-5.

PMID:
15846124
10.

Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.

Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J.

Cancer. 2004 Dec 1;101(11):2557-66.

11.

Xenovaccinotherapy for colorectal cancer.

Seledtsov VI, Niza NA, Felde MA, Shishkov AA, Samarin DM, Seledtsova GV, Seledtsov DV.

Biomed Pharmacother. 2007 Feb-Apr;61(2-3):125-30. Epub 2007 Jan 10.

PMID:
17258887
12.

Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.

Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Ku JH.

Tumori. 2007 Jan-Feb;93(1):68-74.

13.

Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.

Vilella R, Benítez D, Milà J, Lozano M, Vilana R, Pomes J, Tomas X, Costa J, Vilalta A, Malvehy J, Puig S, Mellado B, Martí R, Castel T.

Cancer Immunol Immunother. 2004 Jul;53(7):651-8. Epub 2004 Mar 16.

PMID:
14999431
14.

Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma.

Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ.

Am J Clin Oncol. 2014 Jun;37(3):261-5. doi: 10.1097/COC.0b013e318277d5c8.

15.

Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.

Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M.

Urol Oncol. 2009 Nov-Dec;27(6):598-603. doi: 10.1016/j.urolonc.2008.07.023. Epub 2008 Sep 25.

PMID:
18818106
16.

Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.

Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC, Ku JH.

J Surg Oncol. 2007 Mar 15;95(4):317-23.

PMID:
17066434
17.

Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma.

Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):76-83.

18.

Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.

Amato RJ, Shingler W, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R.

Clin Cancer Res. 2008 Nov 15;14(22):7504-10. doi: 10.1158/1078-0432.CCR-08-0668.

19.

Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.

Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, Evans L, Smith SJ, Stephenson JJ, Wagner TE.

Int J Oncol. 2006 Mar;28(3):585-93.

PMID:
16465362
20.

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.

Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF.

J Clin Oncol. 2008 Apr 20;26(12):2034-9. doi: 10.1200/JCO.2007.14.5193. Epub 2008 Mar 17.

PMID:
18347008

Supplemental Content

Support Center